Dr. Rafael Sanchez-Salas on the ideal patient for focal therapy for prostate cancer

Primary chemoablative therapy with the mitomycin-containing reverse thermal gel UGN-102 induced complete responses in nearly 4 out of 5 patients with low-grade intermediate-risk non–muscle-invasive bladder cancer.

Gopal H. Badlani, MD, and Steven A. Kaplan, MD, discuss some of the notable abstracts in benign urology that were presented at the 2023 AUA Annual Meeting.

The data showed that Black, Hispanic, and uninsured patients were independently associated with a lower likelihood of receiving immunotherapy.

Adam B. Weiner, MD, and Ruchika Talwar, MD, discuss some of the notable urologic oncology abstracts that were presented at the 2023 AUA meeting.

PSMA-PET is becoming an invaluable tool for the diagnosis and management of oligometastatic prostate cancer patients, a sub-group for whom novel treatment strategies are continuing to emerge.

Concomitant abiraterone or enzalutamide did not boost the radium-223 survival benefit in patients with bone-dominant metastatic castration-resistant prostate cancer.